Melanoma Clinical Trials in Ohio

Showing 161-180 of 290 trials

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

NCT04348916

ONCR-177-101 is a phase 1, open-label, multi-center, dose escalation and expansion study of ONCR-177, an oncolytic Herpes Simplex Virus for intratumoral injection, alone and in combination with PD-1 blockade in adult subjects with advanced and/or refractory cutaneous, subcutaneous or metastatic nodal solid tumors or with Liver Metastases of Solid Tumors. The purpose of this study is to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D), as well as to evaluate preliminary efficacy.

CancerMelanomaSolid Tumor+7 more

Oncorus, Inc.66 participantsStarted May 2020

Duarte, California, United States • Denver, Colorado, United States • Tampa, Florida, United States +8 more locations

COMPLETEDPhase 132 miles

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery

NCT02120222

This phase I clinical trial studies the side effects of selinexor in treating patients with melanoma that cannot be removed by surgery. Drugs used in chemotherapy, such as selinexor, may stop the growth of tumor cells, by stopping them from dividing.

Recurrent Melanoma

Kari Kendra8 participantsStarted Aug 2014

Columbus, Ohio, United States

PreviousPage 9 of 15Next

Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors

Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By Surgery

Melanoma Trials in Other Cities

Propranolol Hydrochloride in Treating Patients With Locally Recurrent or Metastatic Solid Tumors That Cannot Be Removed By Surgery

PEG-Interferon Alfa-2b in Treating Patients With Stage IV Melanoma

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

Safety Study of SEA-CD40 in Cancer Patients

Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma

A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors

A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Engaging Moms on Teen Indoor Tanning Through Social Media

A Study of RO7293583 in Participants With Unresectable Metastatic Tyrosinase Related Protein 1 (TYRP1)-Positive Melanomas

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

A Study of PLX2853 in Advanced Malignancies.

A Study of ADXS-NEO Expressing Personalized Tumor Antigens

Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)

Other Conditions in Ohio